Has Archna Bajaj, MD received payments from drug or device companies?

Yes. Drug and device makers reported $48,564 in general payments to Archna Bajaj, MD across 62 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Archna Bajaj, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Archna Bajaj, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Archna Bajaj, MD

Internal Medicine · Philadelphia, PANPI 1093078529

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Chiesi USA, Inc. at 40.1% of the total. 2025 is the largest year on record at $36,179, more than ten times the $59 reported in 2019. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$48,564in general payments, 2019–2025

Across 62 payments — averaging $783.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Chiesi USA, Inc.$19K
Novartis$13K
Regeneron Healthcare Solutions, Inc.$7K
Regeneron$5K
Argenx US, Inc.$1K
Ionis Pharmaceuticals, Inc.$1K
plus $1K from 3 others

$2,922,076in research payments, 2019–2025

Across 125 payments — averaging $23,377 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$894K
Pfizer$626K
Eli Lilly$521K
Novartis$498K
Akcea Therapeutics, Inc.$212K
Regeneron$85K
plus $84K from 2 others

What the payments were for

Consulting fees$26,71555%
Speaking & faculty fees$17,14935%
Travel & lodging$3,2107%
Food & beverage$1,4733%
Education$170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Chiesi USA, Inc.	17	$19,450
Novartis	18	$13,344
Regeneron Healthcare Solutions, Inc.	13	$6,705
Regeneron	8	$5,336
Argenx US, Inc.	1	$1,350
Ionis Pharmaceuticals, Inc.	1	$1,288
Kaneka Medical America LLC	1	$1,000
Amryt Pharma Holdings Ltd	2	$74
Amgen	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

JUXTAPID$18,187
EVKEEZA$11,522
LEQVIO$4,415
VYVGART HYTRULO$1,350
OLEZARSEN$1,288
MYCAPSSA$109

How this compares

$48,564 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$18,211

Medicare patients

130

Services billed

235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Repatha SureclickEvolocumab	218	$228,433
Praluent PenAlirocumab	156	$120,062
VascepaIcosapent Ethyl	25	$14,446
Ezetimibe	213	$9,701
Icosapent Ethyl	15	$3,699
Rosuvastatin Calcium	125	$1,828
FenofibrateFenofibrate Nanocrystallized	14	$907
Atorvastatin Calcium	73	$683
Pravastatin Sodium	12	$232
Lisinopril	15	$115
Amlodipine Besylate	13	$16

Paid to pharmacies, not to this prescriber.

Other internal medicine in Philadelphia

Jonathan EpsteinPhiladelphia$13.1M
Pitamber DevgonPhiladelphia$7.5M
Daniel RaderPhiladelphia$1.7M
David GoldmannPhiladelphia$525K
Eyob FeyssaPhiladelphia$328K
Emil AbramianPhiladelphia$199K
Michael KnightPhiladelphia$178K
James BlakePhiladelphia$164K
Gina SimonciniPhiladelphia$158K
James LewisPhiladelphia$106K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →